Agennix AG has announced that the European Patent Office has issued patent number 1507554, entitled, "Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases," covering the use of oral human lactoferrins, including talactoferrin, to treat cancer.
It also covers the use of talactoferrin in combination with other therapies, including chemotherapy, immunotherapy, radiation therapy and other treatments. The patent has a term until 2023.
Torsten Hombeck, Ph.D., Spokesperson of the Management Board and Chief Financial Officer, said: "This patent further strengthens our intellectual property position for talactoferrin in the area of oncology. This European patent provides broad protection for talactoferrin in this key market, as it covers the use of human lactoferrin for oral administration, used alone or in combination with other therapies, for the treatment of all cancer types. We also have cancer use patents that were recently issued in the U.S. and Japan, two of the other major markets for talactoferrin, that provide protection until 2025 and 2023, respectively, and include coverage for our lead indication, non-small cell lung cancer."